Albert Lowe
Stock Analyst at Craig-Hallum
(3.70)
# 2,213
Out of 4,556 analysts
138
Total ratings
42.2%
Success rate
7.7%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics | Maintained: Buy | n/a | $1.11 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Maintained: Buy | n/a | $3.05 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $142.18 | +44.18% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Maintained: Buy | $6 | $3.58 | +67.60% | 10 | Jun 16, 2026 | |
| CRDF Cardiff Oncology | Downgraded: Hold | $2 | $0.86 | +132.56% | 13 | Jun 4, 2026 | |
| NGNE Neurogene | Maintained: Buy | $65 | $36.11 | +80.01% | 7 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Maintained: Buy | $25 → $12 | $1.27 | +848.62% | 9 | May 12, 2026 | |
| CMPX Compass Therapeutics | Maintained: Buy | n/a | $2.04 | - | 6 | May 6, 2026 | |
| TSX: EPRX Eupraxia Pharmaceuticals Inc. | Reiterated: Buy | $19.75 | $9.10 | +116.98% | 12 | May 5, 2026 | |
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $140 | $44.60 | +213.90% | 1 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.35 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.6402 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $5.00 | -20.00% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.43 | +311.52% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.72 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $14.42 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $1.33 | +200.75% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $11.70 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $312.19 | n/a | 1 | Jun 4, 2024 |
Lineage Cell Therapeutics
Jul 14, 2026
Maintained: Buy
Price Target: n/a
Current: $1.11
Upside: -
Opus Genetics
Jul 6, 2026
Maintained: Buy
Price Target: n/a
Current: $3.05
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $142.18
Upside: +44.18%
SAB Biotherapeutics
Jun 16, 2026
Maintained: Buy
Price Target: $6
Current: $3.58
Upside: +67.60%
Cardiff Oncology
Jun 4, 2026
Downgraded: Hold
Price Target: $2
Current: $0.86
Upside: +132.56%
Neurogene
May 15, 2026
Maintained: Buy
Price Target: $65
Current: $36.11
Upside: +80.01%
Actuate Therapeutics
May 12, 2026
Maintained: Buy
Price Target: $25 → $12
Current: $1.27
Upside: +848.62%
Compass Therapeutics
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $2.04
Upside: -
Eupraxia Pharmaceuticals Inc.
May 5, 2026
Reiterated: Buy
Price Target: $19.75
Current: $9.10
Upside: +116.98%
Spruce Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $140
Current: $44.60
Upside: +213.90%
Apr 2, 2026
Maintained: Buy
Price Target: n/a
Current: $4.35
Upside: -
Mar 11, 2026
Maintained: Hold
Price Target: n/a
Current: $0.6402
Upside: -
Feb 17, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $5.00
Upside: -20.00%
Feb 12, 2026
Maintained: Buy
Price Target: $10
Current: $2.43
Upside: +311.52%
Jan 23, 2026
Maintained: Buy
Price Target: n/a
Current: $3.72
Upside: -
Jan 12, 2026
Maintained: Buy
Price Target: n/a
Current: $14.42
Upside: -
Nov 13, 2025
Maintained: Buy
Price Target: $4
Current: $1.33
Upside: +200.75%
Jun 6, 2024
Maintained: Buy
Price Target: n/a
Current: $11.70
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $312.19
Upside: n/a